Low Uptake Limits Benefits of Maternal RSV Vaccination
5 Articles
5 Articles
Global study finds stark differences in maternal RSV vaccine uptake
Vaccination against a common respiratory virus during pregnancy lowers the risk of severe disease in babies by 74%, but uptake in many countries remains low, a new review suggests. The report also reveals evidence of lower uptake of the respiratory syncytial virus (RSV) vaccine among some socioeconomic and ethnic groups, those with reduced access to health care and younger mothers.
Vaccination against the syncitial respiratory virus (SVR) during pregnancy reduces the risk of hospitalization in infants under six months of age, according to a new international study published in the scientific journal The Lancet Regional Health – Europe. The University of Granada (UGR) has participated in this research, in collaboration with the University of Edinburgh. The VRS represents one of the main causes of respiratory infections in t…
BIOENGINEER.ORG
Scienmag: Latest Science and Health NewsMaternal RSV vaccine shields babies but global uptake lags far behind
A systematic review of more than four million pregnancies finds maternal RSV vaccination cuts severe infant disease by 74 per cent, yet coverage remains low and uneven across countries and communities.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
